16,476 results match your criteria Irritable Bowel Syndrome


Letter: gut-brain axis dysfunction underlies symptom generation in irritable bowel syndrome-a plea for rational interpretation of irrational doses of FODMAPs. Authors' reply.

Aliment Pharmacol Ther 2022 Jul;56(2):368-369

Laboratory for Brain-Gut Axis Studies (LaBGAS), Translational Research Centre for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases & Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.

View Article and Full-Text PDF

Letter: gut-brain axis dysfunction underlies symptom generation in irritable bowel syndrome-a plea for rational interpretation of irrational doses of FODMAPs.

Aliment Pharmacol Ther 2022 Jul;56(2):366-367

Department of Gastroenterology, Central Clinical School, Monash University, Melbourne, Victoria, Australia.

View Article and Full-Text PDF

A Method of Generating a Classifier that Determines the Presence or Absence of IBS Symptoms by Supervised Learning from the Frequency Analysis of Electroencephalogram Data.

Front Biosci (Landmark Ed) 2022 Jun;27(6):187

Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, 980-8575 Miyagi, Japan.

Background: Young adults with irritable bowel syndrome (IBS) occasionally exhibit specific abdominal symptoms, including abdominal pain associated with brain activity patterns. Decoded neural feedback (DecNef) is a biofeedback exercise that allows symptomatic people to exercise self-control over their brain activity patterns relative to those without symptoms. Thus, DecNef can be used to self-control abdominal pain in patients with IBS. Read More

View Article and Full-Text PDF

Do Socio-Demographics Play a Role in the Prevalence of Red Flags and Pursuant Colonoscopies in Patients With Irritable Bowel Syndrome?

Cureus 2022 May 19;14(5):e25137. Epub 2022 May 19.

Department of Gastroenterology and Hepatology, Rutgers University New Jersey Medical School, Newark, USA.

Background Irritable bowel syndrome (IBS) is a "brain-gut disorder" that lacks laboratory, radiologic, or physical exam findings. Colonoscopies are not routinely performed unless "red flag" symptoms, such as bleeding or abnormal weight loss, are present. Socio-demographics have been implicated as sources of potential disparities in appropriate care. Read More

View Article and Full-Text PDF

Enterococci-Involvement in Pathogenesis and Therapeutic Potential in Cancer Treatment: A Mini-Review.

Pathogens 2022 Jun 15;11(6). Epub 2022 Jun 15.

Department of Hygiene of Animal Feeding Stuffs, National Veterinary Research Institute, Partyzantow 57, 24-100 Pulawy, Poland.

spp. are Gram-positive, heterogeneous lactic acid bacteria inhabiting various environments. Several species of Enterococci are considered to be able to stimulate the immune system and play an important role in intestinal homeostasis. Read More

View Article and Full-Text PDF

Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials.

Nutrients 2022 Jun 15;14(12). Epub 2022 Jun 15.

Health Technology Assessment Center, Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou 730000, China.

To perform a systematic review and meta-analysis to evaluate the effectiveness and safety of probiotics in the treatment of constipation-predominant irritable bowel syndrome (IBS-C), we searched for randomized controlled trials (RCTs) comparing probiotic care versus placebos for patients with IBS-C in five comprehensive databases (March 2022). The risk of bias was assessed using the Cochrane Collaboration Risk of Bias Tool. RevMan 5. Read More

View Article and Full-Text PDF

An Open-Label Trial Study of Quality-of-Life Assessment in Irritable Bowel Syndrome and Their Treatment.

Medicina (Kaunas) 2022 Jun 5;58(6). Epub 2022 Jun 5.

Faculty of Medicine and Pharmacy, Medicine Department, University of Oradea, 410068 Oradea, Romania.

Irritable bowel syndrome (IBS) does not only have a complex pathophysiological evolution with central and peripheral mechanisms. This study aimed to monitor the neuropsychiatric part of IBS and its management, following the quality of life of patients with IBS. Participants numbering 145 were investigated in this study for 6 months and were divided into four groups, namely the control group with a symptomatic period of less than 6 months ( = 34), the group with irritable bowel syndrome (IBS; = 58), IBS and neuropsychiatric treatment ( = 32), and IBS with probiotic treatment ( = 22). Read More

View Article and Full-Text PDF

A patient with familial Mediterranean fever mimicking diarrhea-dominant irritable bowel syndrome who successfully responded to treatment with colchicine: a case report.

J Med Case Rep 2022 Jun 24;16(1):247. Epub 2022 Jun 24.

Department of General Medicine, Asahikawa Medical University, Asahikawa, Japan.

Background: Irritable bowel syndrome is a functional gastrointestinal disease. Visceral hypersensitivity is the most important pathophysiology in irritable bowel syndrome. Currently, diagnosis of irritable bowel syndrome is based on symptoms and exclusion of other organic diseases. Read More

View Article and Full-Text PDF

AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.

Gastroenterology 2022 Jul;163(1):137-151

Department of Medicine, University of Tennessee College of Medicine, Memphis, Tennessee.

Background & Aims: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder associated with significant disease burden. This American Gastroenterological Association Guideline is intended to support practitioners in decisions about the use of medications for the pharmacological management of IBS with predominant diarrhea (IBS-D) and is an update of a prior technical review and guideline.

Methods: The Grading of Recommendations Assessment, Development and Evaluation framework was used to assess evidence and make recommendations. Read More

View Article and Full-Text PDF

AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation.

Gastroenterology 2022 Jul;163(1):118-136

Department of Family Medicine, University of Michigan Medical School, Ann Arbor, Michigan.

Background & Aims: Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction associated with significant disease burden. This American Gastroenterological Association guideline is intended to support practitioners in decisions about the use of medications for the pharmacological management of IBS-C and is an update of a prior technical review and guideline.

Methods: The Grading of Recommendations Assessment, Development and Evaluation framework was used to assess evidence and make recommendations. Read More

View Article and Full-Text PDF

Further research needed to determine first-line therapy for IBS in primary care.

Gut 2022 Jun 22. Epub 2022 Jun 22.

Academic Unit of Gastroenterology, Royal Hallamshire Hospital, Sheffield, UK.

View Article and Full-Text PDF

Pandemic-Related Social Disruption and Well-Being in Pediatric Gastrointestinal Diseases.

J Pediatr Psychol 2022 Jun 22. Epub 2022 Jun 22.

Division of Gastroenterology, Hepatology, & Nutrition, Emory University School of Medicine, USA.

Objective: The coronavirus disease 2019 (COVID-19) pandemic has impacted everyone, but there are few data regarding how the pandemic has influenced the lives of children with gastrointestinal (GI) conditions. This cross-sectional study assessed pandemic-related social disruption (PRSD) in children with inflammatory bowel disease (IBD), celiac disease (CD), and irritable bowel syndrome (IBS), and the potential buffering effect of the parent-child relationship.

Methods: A survey completed between September and December 2020 asked 146 children (ages 8-17) diagnosed with IBD (n = 44), CD (n = 81), or IBS (n = 51) and 185 parents how the pandemic has contributed to social disruption (i. Read More

View Article and Full-Text PDF

Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: a systematic review with meta-analysis.

Am J Clin Nutr 2022 Jun 21. Epub 2022 Jun 21.

Food & Mood Centre, Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University, Victoria, Australia.

Background: A low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) diet is increasingly used to manage symptoms in irritable bowel syndrome (IBS). While this approach may alter the colonic microbiome, the nature of these changes has not been comprehensively synthesized.

Objectives: The aim of this study was to conduct a systematic review with meta-analysis of randomized controlled trials (RCTs) examining the impact of a low FODMAP diet on the composition and function of the microbiome in patients with IBS. Read More

View Article and Full-Text PDF

NCDO2118 exerts visceral antinociceptive properties in rat via GABA production in the gastro-intestinal tract.

Elife 2022 Jun 21;11. Epub 2022 Jun 21.

Toulouse Biotechnology Institute (TBI), Université de Toulouse, CNRS, INRAE, INSA, Toulouse, France.

Gut disorders associated to irritable bowel syndrome (IBS) are combined with anxiety and depression. Evidence suggests that microbially produced neuroactive molecules, like γ-aminobutyric acid (GABA), can modulate the gut-brain axis. Two natural strains of and one mutant were characterized for their GABA production and tested in rat by oral gavage for their antinociceptive properties. Read More

View Article and Full-Text PDF

Irritable bowel syndrome with food-related symptoms: Future directions in the clinical management.

United European Gastroenterol J 2022 Jun 21. Epub 2022 Jun 21.

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

The majority of patients with irritable bowel syndrome (IBS) experiences food-related symptoms, which are associated with high symptom burden, reduced quality of life, increased healthcare consumption and reduced intake of certain nutrients. In this review we aimed to describe a clinically useful approach for physicians, by presenting the latest progress in knowledge and its translation to management in IBS patients with food-related symptoms, as well as the underlying mechanisms involved. The research tools currently available that can be used in the future for a better characterization of this subgroup of patients are also discussed. Read More

View Article and Full-Text PDF

Symptoms Compatible with Rome IV Functional Bowel Disorder in Patients with Ankylosing Spondylitis.

Mod Rheumatol 2022 Jun 21. Epub 2022 Jun 21.

Department of Rheumatology and Immunology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.

Objectives: To determine the frequency of symptoms meeting Rome IV functional bowel disorder (FBD) in patients with ankylosing spondylitis (AS), investigate factors associated with FBD symptoms, and assess whether having FBD symptoms might influence AS disease activity.

Methods: In this cross-sectional study, we enrolled 153 AS patients without known colonic ulcer and 56 sex- and age-matched controls to evaluate FBD (or its subtypes) symptoms. Disease characteristics were also evaluated in AS group. Read More

View Article and Full-Text PDF

Colonic mucosal microbiota is associated with bowel habit subtype and abdominal pain in patients with irritable bowel syndrome.

Am J Physiol Gastrointest Liver Physiol 2022 Jun 21. Epub 2022 Jun 21.

G Oppenheimer Center for Neurobiology of Stress and Resilience, Los Angeles, CA, United States.

Background And Aims: There is growing evidence that mucosal microbiota differs significantly from fecal microbiota in irritable bowel syndrome (IBS) and may play a different role in its pathophysiology. The aims of this study were to determine if the composition of mucosal microbiota differed between IBS, or IBS bowel habit (BH) subtypes, and healthy controls (HCs).

Methods: Sigmoid colon mucosal biopsies were obtained from 97 Rome positive IBS patients (28% IBS-Constipation, 38% IBS-Diarrhea, 24% IBS-Mixed, and 10% IBS-Unsubtyped) and 54 HCs, from which DNA was extracted. Read More

View Article and Full-Text PDF

Anxiety in the Medically Ill: A Systematic Review of the Literature.

Front Psychiatry 2022 3;13:873126. Epub 2022 Jun 3.

Department of Health Sciences, University of Florence, Florence, Italy.

Background: Although anxiety is highly represented in the medically ill and its occurrence has relevant clinical implications, it often remains undetected and not properly treated. This systematic review aimed to report on anxiety, either symptom or disorder, in patients who suffer from a medical illness.

Methods: English-language papers reporting on anxiety in medically ill adults were evaluated. Read More

View Article and Full-Text PDF

Kimchi improves irritable bowel syndrome: results of a randomized, double-blind placebo-controlled study.

Food Nutr Res 2022 23;66. Epub 2022 May 23.

Department of Food Science and Biotechnology, Cha University, Seongnam, Gyeonggi-do, Republic of Korea.

Background: Irritable bowel syndrome (IBS) can be caused by abnormal bowel movements, altered brain-gut axis, gut microbiota change, and low levels of inflammation or immune activation. The intake of food containing much fiber and lactic acid bacteria (LABs) can alleviate IBS.

Objective: This study was undertaken to confirm the alleviative effect of kimchi on symptoms of IBS. Read More

View Article and Full-Text PDF

The Effect of Serine Protease Inhibitors on Visceral Pain in Different Rodent Models With an Intestinal Insult.

Front Pharmacol 2022 2;13:765744. Epub 2022 Jun 2.

Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium.

Serine proteases are believed to play a key role in the origin of abdominal pain in IBD and IBS. We previously demonstrated a reduction of visceral pain in a post-inflammatory IBS rat model after a single intraperitoneal or intracolonic administration of a serine protease inhibitor. The aim of this study was to investigate the efficacy of serine protease inhibition on visceral pain in two different animal models involving a colonic insult based either on acute inflammation or on neonatal irritation. Read More

View Article and Full-Text PDF

Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials.

Front Nutr 2022 27;9:890357. Epub 2022 May 27.

Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.

Background: Gut microbiota has been identified as an imbalance in patients with irritable bowel syndrome (IBS). Fecal microbiota transplantation (FMT) is a novel method to restore microbiota and treat IBS patients.

Objective: To conduct a meta-analysis and estimate the efficacy and safety of FMT for the treatment of IBS patients with subgroup analyses to explore the most effective way of FMT for IBS. Read More

View Article and Full-Text PDF

Enterochromaffin Cells-Gut Microbiota Crosstalk: Underpinning the Symptoms, Pathogenesis, and Pharmacotherapy in Disorders of Gut-Brain Interaction.

J Neurogastroenterol Motil 2022 Jun 20. Epub 2022 Jun 20.

Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.

Disorders of gut-brain interaction (DGBIs) are common conditions in community and clinical practice. As specialized enteroendocrine cells, enterochromaffin (EC) cells produce up to 95% of total body serotonin and coordinate luminal and basolateral communication in the gastrointestinal (GI) tract. EC cells affect a broad range of gut physiological processes, such as motility, absorption, secretion, chemo/mechanosensation, and pathologies, including visceral hypersensitivity, immune dysfunction, and impaired gastrointestinal barrier function. Read More

View Article and Full-Text PDF

Risk Factors for Abdominal Pain Disorders of Gut Brain Interaction in Adults and Children: A Systematic Review.

Gastroenterology 2022 Jun 15. Epub 2022 Jun 15.

Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA. Electronic address:

Background And Aims: Many studies have assessed risk factors of irritable bowel syndrome (IBS) and other abdominal pain-related disorders of gut-brain interaction (AP-DGBI); however, the role of these factors is unclear due to heterogeneous study designs. The aim of this systematic review was to extensively evaluate the literature and determine clinical risk and protective factors for the presence and persistence of AP-DGBI in children and adults.

Methods: A PubMed search identified studies investigating potential risk and protective factors for AP-DGBI in adults and children. Read More

View Article and Full-Text PDF

Endometriosis and irritable bowel syndrome: similarities and differences in the spectrum of comorbidities.

Hum Reprod 2022 Jun 17. Epub 2022 Jun 17.

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.

Study Question: Do the spectrum and prevalence of comorbidities of endometriosis and irritable bowel syndrome (IBS) overlap?

Summary Answer: Despite several overlapping symptoms, the most significantly associated comorbidities of endometriosis and IBS are different and are rather related to the organ systems primarily involved in the index diagnosis.

What Is Known Already: Endometriosis and IBS both have several similar unspecific symptoms, such as recurrent abdominal pain, cramping and anxiety, and both diseases affect young women and are associated with a number of comorbidities causing a poor quality of life. However, a detailed study, revealing the full spectrum of endometriosis and IBS comorbidities in the same study population, is lacking. Read More

View Article and Full-Text PDF

[Anti-inflammation effect of moxibustion for rats with diarrhea-predominant irritable bowel syndrome based on multiple miRNAs regulating NF-κB signal pathway].

Zhongguo Zhen Jiu 2022 Jun;42(6):654-62

Second Affiliated Hospital of Anhui University of CM, Hefei 230061; Anhui Acupuncture Clinical Medical Research Center, Hefei 230061; Clinical Institute of Acupuncture and Moxibustion, Anhui Academy of TCM, Hefei 230038.

Objective: To observe the effect of moxibustion on the regulation of nuclear factor-kappa B (NF-κB) and inflammatory factors by multiple microRNAs (miRNAs) in rats with diarrhea-predominant irritable bowel syndrome (IBS-D), and to explore the anti-inflammatory mechanism of moxibustion on IBS-D.

Methods: Twelve of 52 newborn rats were randomly selected into a normal group. The remaining rats were made into IBS-D model. Read More

View Article and Full-Text PDF

Undiagnosed Exocrine Pancreatic Insufficiency in Diarrhea-Predominant Irritable Bowel Syndrome.

Dig Dis Sci 2022 Jun 15. Epub 2022 Jun 15.

Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 45 Francis Street, Boston, MA, 02115, USA.

View Article and Full-Text PDF

Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at three years after transplantation.

Gastroenterology 2022 Jun 13. Epub 2022 Jun 13.

Department of Clinical Medicine and Department of Gastroenterology, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway.

Background & Aims: The long-term efficacy and possible adverse events of fecal microbiota transplantation (FMT) for IBS are unknown. This study performed a 3-year follow-up of the patients in our previous clinical trial to clarify these aspects.

Methods: This study included 125 patients (104 females, and 21 males): 38 in a placebo group, 42 who received 30 g of donor feces, and 45 who received 60 g of donor feces. Read More

View Article and Full-Text PDF

The Belgian consensus on irritable bowel syndrome: the paediatric gastroenterologist view.

Acta Gastroenterol Belg 2022 Apr-Jun;85(2):384-386

Vrije Universiteit Brussel, UZ Brussel, KidZ Health Castle, Brussels, Belgium.

View Article and Full-Text PDF

Belgian consensus on irritable bowel syndrome.

Acta Gastroenterol Belg 2022 Apr-Jun;85(2):360-382

Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.

Background: Irritable bowel syndrome (IBS) is characterised by recurrent abdominal pain related to defaecation or associated with altered stool frequency or consistency. Despite its prevalence, major uncertainties in the diagnostic and therapeutic management persist in clinical practice.

Methods: A Delphi consensus was conducted by 20 experts from Belgium, and consisted of literature review and voting process on 78 statements. Read More

View Article and Full-Text PDF

Essential reading from the editor's desk.

Acta Gastroenterol Belg 2022 Apr-Jun;85(2):255-256

Gastroenterology, University Hospital Liège, Liège, Belgium.

View Article and Full-Text PDF